Chief & Presenting Author: Dr.Mrinalini Singh

Co Author(s): Dr.Sanjay Kumar Mishra, Prof. Dr.Pradeep Kumar, Dr.Srishti Khullar

Abstract

Study design: Prospective observational study from 2021 onwards.
Purpose: To study the serious ocular adverse events (SOAE) with intravitreal brolucizumab and treatment strategies to manage them.
Methods: 1420 patients with neovascular age-related macular degeneration, diabetic macular edema and polypoidal choroidal vasculopathy, were followed for 6 months post intravitreal brolucizumab. Best corrected visual acuity and serious ocular adverse events were assessed pre-injection, 1 week, 1 month and 6 months post-injection.
Results: 2 SOAE occurring in nAMD patients were managed with steroids with resolution at 01 month and 03 days, respectively. 2 SOAE occurring in DME patients, were managed with posterior subtenons triamcinolone acetonide, with remission in 5 and 7 days respectively. 3 out of 4 cases well tolerated repeat injection of brolucizumab.
Conclusion: 4 cases out of 1420 of SOAE have been noticed till date and were managed without loss of visual acuity.